Sign In
Buy TRCK
$0.643
-0.0072 (-1.11%)
At Close: Jul 31, 2026
GM "Solid" Quarter, Tariff Uncertainty Drives Stock Off-Track
01:30pm, Tuesday, 29'th Apr 2025
General Motors (GM) posted an earnings beat but delayed its conference call due to a lack of clarity on tariffs. Karl Brauer says the Trump administration needs to focus on long-term tariff plans to e
TAP's Innovations on Track: Topo Chico Hard Debuts Margarita Beverages
01:25pm, Tuesday, 29'th Apr 2025
Molson Coors is focused on portfolio premiumization and innovations. Topo Chico Hard Seltzer is extending its portfolio into flavored alcoholic beverages.
Honeywell Stock Surges On Q1 Beat, Hiked Earnings; Spinouts On Track
08:35am, Tuesday, 29'th Apr 2025
Honeywell stock jumps on Q1 results, hiked earnings outlook. The Dow Jones firm's planned separations are still expected next year.
Deutsche Bank Sees Full-Year Targets on Track After Profit, Revenue Rise
01:46am, Tuesday, 29'th Apr 2025
The group saw growth in its investment bank, private bank and asset management arms offsetting a decline in its corporate bank.
Chinese Robotaxi Firm Pony AI on Faster Track to Profit After Cost Cuts, CTO Says
06:23am, Monday, 28'th Apr 2025
The Chinese robotaxi company says it is getting closer to profitability after clearing a cost hurdle its chief technology officer believes can help unlock the commercialization of driver-less vehicles
Pepsi and Other Food Stocks Are Broken. How They Get Back on Track.
01:45am, Friday, 25'th Apr 2025
Big food companies raised prices more than they needed to during the pandemic, and are now paying the price as consumers look for cheaper—and healthier—alternatives
PG&E Corporation Reports First-Quarter Results; On Track to Deliver Solid 2025; Residential Electric Rates Lower Today Than a Year Ago
06:05am, Thursday, 24'th Apr 2025
OAKLAND, Calif. , April 24, 2025 /PRNewswire/ -- PG&E Corporation (NYSE: PCG) is on track to deliver solid 2025 financial results.
Verizon Posts Earnings Beat, Stays on Track for Full-Year Outlook
07:30am, Tuesday, 22'nd Apr 2025
Verizon Communications surpassed expectations with its first-quarter earnings and said it is still on course to meet its yearly goals.
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
04:05pm, Monday, 21'st Apr 2025
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DV
Tariff-Resistant Abbott Laboratories on Track for New Highs
07:37am, Thursday, 17'th Apr 2025
Abbott Laboratories NYSE: ABT is not immune to the impact of tariffs on its medical device business. However, the company's diversified business is tariff-resistant, and moves are being made to streng
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'
10:56am, Wednesday, 16'th Apr 2025
VERV's VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102's development later this year, which would help VERV by covering one-third of the
Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer
08:00am, Wednesday, 16'th Apr 2025
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) is one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
12:50pm, Friday, 11'th Apr 2025
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
07:00am, Friday, 11'th Apr 2025
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and D
